Zenyaku Ends Japan Alliance With Anthera
This article was originally published in Scrip
US firm Anthera Pharmaceuticals Inc.'s development partner in Japan for autoimmune disorder drug blisibimod has served a termination notice for the late 2014 deal, but the US firm says the impact could in fact be positive.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.